The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Target Validation, 2011Ghrelin Agonist as a Novel Therapeutic Approach to Alleviate Gut Dysmotility and Levodopa-inhibited Gastric Emptying in PD Models
Objective/Rationale:
Patients with Parkinson’s disease (PD) have altered progression of ingested aliments/liquid from their stomach to the intestine, as well as suffer from constipation, and there is...
-
MJFF Research Grant, 2011Structural, Post-translational Modification and Small Chemical Approaches to Understand LRRK2 Function in PD
Promising Outcomes of Original Grant:
Our original goal was to (1) establish electron microscopy (EM)-based dimeric structural assays for the LRRK2 protein and (2) develop high-throughput kinase assays... -
LRRK2, 2011Analytic Models in Biomarker Development
Objective/Rationale:
Non-invasive tests or biomarkers may aid clinical trials if they help to identify a subgroup of individuals at high risk of Parkinson's disease (PD), or if they are able to... -
Improving Levodopa Delivery, 2012Enhanced Dopamine Availability, Prolonged Activity and Improved Dyskinesia Profile After Administration of Selectively Deuterated Levodopa
Objective/Rationale:
To confirm the found beneficial effects of DP-102 (reduced dyskinetic effects at motoric equieffective doses in comparison to regular levodopa) in a pre-clinical model of Parkinson... -
LRRK2 Biology LEAPS, 2012Combining Mass Spectrometry with Genetic and Pharmacological Approaches to Discover and Validate LRRK2 Substrates
Objective/Rationale:
Much recent work has suggested that comprehending the biological properties of an enzyme termed LRRK2 that is mutated in about one percent of all Parkinson’s disease patients... -
Therapeutic Pipeline Program, 2015Orexin Receptor Modulators for the Treatment of Circadian Sleep-wake Disorders in Parkinson's Disease
Study Rationale:
Reset Therapeutics, Inc. (Reset) will develop a new therapy to address excessive daytime sleepiness, a common non-motor symptom in Parkinson’s disease (PD). The natural daily rhythm of...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.